A Phase 2a Multicenter Clinical Trial of TB006 in Participants with Parkinson's Disease

Description

The primary objectives of this study are to assess the efficacy of TB006 in improving motor function and to assess the safety of TB006 in participants with Parkinson's Disease (PD).

Conditions

Parkinson's Disease (PD)

Study Overview

Study Details

Study overview

The primary objectives of this study are to assess the efficacy of TB006 in improving motor function and to assess the safety of TB006 in participants with Parkinson's Disease (PD).

A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of TB006 in Participants with Parkinson's Disease

A Phase 2a Multicenter Clinical Trial of TB006 in Participants with Parkinson's Disease

Condition
Parkinson's Disease (PD)
Intervention / Treatment

-

Contacts and Locations

Indianapolis

Josephson Wallack Munshower Neurology - Southeast, Indianapolis, Indiana, United States, 46256

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Participants voluntarily agree to participate in this study and sign an Institutional Review Board (IRB)-approved informed consent form (ICF) prior to performing any of the screening procedures.
  • 2. Diagnosis of Parkinson's disease (PD) with motor symptom improvement from levodopa, if applicable.
  • 3. Less than 5 years from the initial PD diagnosis, at the time of ICF.
  • 4. Early-stage PD, with mild symptoms based on standard clinical staging in OFF state.
  • 5. Participants who are on immediate-release levodopa-carbidopa/benserazide.
  • 6. No active cancer, unless in remission for ≥10 years without ongoing treatment, except fully removed basal cell carcinoma.
  • 7. Free of significant health issues that might interfere with study participation.
  • 8. Negative screening for illegal drugs (excluding cannabis), with willingness to abstain during the study and avoid cannabis or alcohol effects during visits.
  • 1. History of sudden, unexpected PD medication OFF episodes.
  • 2. Severe motor complications or disabling symptoms that may impact study involvement.
  • 3. Any condition or health concern deemed a safety risk or likely to interfere with study results.
  • 4. Severe psychiatric disorders, including psychosis or substance addiction.
  • 5. Allergies or sensitivities to specific study-related treatments or substances.
  • 6. Any prior history of a severe infusion reaction.
  • 7. Pregnancy, breastfeeding, or plans for pregnancy or ova donation during or shortly after the study.
  • 8. Recent use of investigational drugs or therapeutic antibodies.

Ages Eligible for Study

50 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

TrueBinding, Inc.,

Study Record Dates

2025-12-29